Table 1.
Baseline characteristics of patients in the three HIR cohorts.
| GOG-249 (n = 473) |
PORTEC-2 (n = 184) |
ESMO-ESGO-ESTRO (n = 204) |
|
|---|---|---|---|
| Time periods | |||
| 1999–2005 | 30 (6.3%) | 16 (8.7%) | 10 (4.9%) |
| 2005–2010 | 70 (14.8%) | 27 (14.7%) | 33 (16.2%) |
| 2010–2015 | 373 (78.9%) | 141 (76.6%) | 161 (78.9%) |
| Age | |||
| ≤60 years | 309 (65.3%) | 0 (0%) | 143 (70.1%) |
| >60 years | 164 (34.7%) | 184 (100%) | 61 (29.9%) |
| FIGO stage | |||
| IA | 59 (12.5%) | 29 (15.8%) | 159 (77.9%) |
| IB | 279 (60.0%) | 155 (84.2%) | 45 (22.1%) |
| II | 135 (28.5%) | 0 (0%) | 0 (0%) |
| Lymphovascular invasion | |||
| no | 332 (70.2%) | 163 (88.6%) | 92 (45.1%) |
| yes | 141 (29.8%) | 21 (11.4%) | 112 (54.9%) |
| Histologic grade | |||
| Grade 1 | 66 (14.0%) | 69 (37.5%) | 30 (14.7%) |
| Grade 2 | 278 (58.8%) | 84 (45.7%) | 68 (33.3%) |
| Grade 3 | 129 (27.2%) | 31 (16.8%) | 106 (52%) |
| Radiation therapy modality | |||
| VBT | 147 (31.1%) | 95 (51.6%) | 102 (50%) |
| EBRT ± VBT | 326 (68.9%) | 89 (48.4%) | 102 (50%) |
| Chemotherapy | |||
| yes | 100 (21.1%) | 24 (13%) | 53 (26%) |
| no | 335 (70.8%) | 140 (76.1%) | 133 (65.2%) |
| missing | 38 (8.0%) | 20 (10.9%) | 18 (8.8%) |
| Received lymph node dissection | |||
| yes(pN0) | 339 (71.7%) | 119 (64.5%) | 155 (76%) |
| Full dissection | 303 (89.4%) | 106 (89.1%) | 134 (86.5%) |
| SLN | 36 (10.6%) | 13 (10.9%) | 21 (13.5%) |
| no(cN0) | 134 (28.3%) | 65 (35.3%) | 49 (24.0%) |